MA-PRECISELY
28.2.2024 15:01:36 CET | Business Wire | Press release
Precisely, the global leader in data integrity, today announced that Etam Group, a major international retailer and leading lingerie brand in France, has implemented its Automate Studio solution across all subsidiaries to support company-wide accounts payable processes. By providing seamless SAP data access to decision-makers in real-time, Automate Studio (formerly Winshuttle Studio) enables Etam’s accounting teams to work autonomously without support from IT personnel, reduce operational costs, and drive greater innovation across the organization.
Business agility is critical in the retail industry, with companies seeking to balance tight margins with the need to innovate and stay competitive. With more pressure than ever to optimize margins through existing operating structures and processes, it comes as no surprise that automation has emerged as a top consideration for retailers in 2024. Retail companies are increasingly seeing the need to simplify and accelerate processes across their major functions to drive business efficiencies, improve customer experience, and stay compliant with an ever-changing regulatory landscape.
“In the retail sector, businesses must stay agile and be able to implement ideas quickly, something which is also incredibly important in accounting,” said Stéphane Delattre, Vice President – Accounting for Europe at Etam Group. “Automate Studio increases our productivity and efficiency, enabling mass data simplification and empowering decision-makers to access trustworthy data in real-time. We call it the ‘miracle product’!”
The Etam Group has an impressive history of driving innovation to optimize infrastructure and provide great customer experience – having invented the concept of just-in-time automatic restocking in 1965. But with presence now in over 1,500 stores located across 57 countries, the retailer needed a solution that would work with its SAP ERP (enterprise resource planning) software and support all the company’s subsidiaries in streamlining their data management.
Automate Studio is the premier Excel-to-SAP solutions platform that enables business users to automate complex SAP business processes and make mass data changes quickly and easily. The platform allows customers to eliminate manual data entries and upload and download SAP data in record time, while simultaneously improving data quality. Automate Studio empowers business teams by reducing their reliance on IT support for automating Excel to SAP processes. Now citizen developers within business teams can create and manage their own solutions faster, while ensuring compliance and security standards are maintained.
“Before we deployed Automate Studio, we manually handled hundreds of invoices a month which could be very time-consuming,” said Delattre. “This practical solution from Precisely has not only increased our internal productivity but has helped us save time. Previously, one invoice took three minutes to create and now Automate Studio facilitates the creation of nearly 600 invoices within 15 minutes. Another example is how drastically it reduced the time needed to add purchasing conditions to orders in SAP – this used to take two days but can now be completed in just two hours.”
“Precisely is committed to helping customers automate their SAP processes to maintain agility, accelerate speed of business, and build the integrity of their data,” said Pat McCarthy, Chief Revenue Officer at Precisely. “As more organizations embark on digital transformation across their core functions, they are realizing the power of process automation, fueled by accurate, consistent, and contextual data to help ensure success.”
Learn more about Precisely Automate Studio.
About Etam Group
One hundred years old, still family-owned and independent, the Etam Group, now a leader in France and internationally, is a key player in innovative and creative lingerie and fashion. With its identity and historical know-how, the Etam Group cultivates this unique relationship with its customers through its brands Etam, Maison 123, Undiz Livy and Ysé, and a strong omnichannel presence based on more than 1500 stores in 57 countries. Learn more at https://etam-groupe.com
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228517820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom